Back to News & Events

SBIR/STTR Omnibus Webinar Recording, Transcript, and Slides Available

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Program recently hosted a webinar to assist interested applicants with understanding proposal preparation, federal guidelines and resources, the funding process, and address general concerns.

The webinar presentation, recording, and transcript are now available (via web and attachments) for your reference. (Please be advised, an automated transcription service was used, and there may be grammatical errors and typos in the transcript.) We have done our best to correct as many errors as possible, but you are encouraged to reach out to us by email at sbir@od.nih.gov if anything remains unclear.
– Webinar Slides
– Recording
Transcript

HHS SBIR and STTR Omnibus grant solicitations permit researcher-initiated topics around health, medicine and life science to be submitted for funding consideration. With any specific idea, you should speak directly with a HHS SBIR/STTR program manager at least a month BEFORE the deadline to gauge their interest.

You can find the HHS SBIR/STTR Omnibus Solicitations, and all of other SBIR/STTR solicitations on the Funding page of the SBIR/STTR Website: https://sbir.nih.gov/funding.

Be sure to also check the targeted funding announcements page, https://sbir.nih.gov/funding/individual-announcements. NIH Institutes and Centers will issue targeted SBIR/STTR grant solicitations around specific, high-priority research areas.

The next submission deadline is September 5, 2019.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4488
                    [post_author] => 4
                    [post_date] => 2024-10-24 10:45:00
                    [post_date_gmt] => 2024-10-24 14:45:00
                    [post_content] => 

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2024-12-05 11:35:07 [post_modified_gmt] => 2024-12-05 16:35:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3642 [post_author] => 1 [post_date] => 2020-10-16 14:51:06 [post_date_gmt] => 2020-10-16 14:51:06 [post_content] =>

Applications for the Center for Biotechnology's Fundamentals of the Bioscience Industry Program are open!

This innovative, one semester, evening program provides participants with the skills and knowledge they need to transition out of the academic lab into a professional position in the bioscience industry and an overall introduction to the technology commercialization process.  The program is taught by industry professionals through lectures and interactive team projects. Students gain first-hand experience in the development of commercialization strategies around real intellectual property and business issues. This experiential learning process will shed light onto the expanded number of business roles to which scientific skills can be applied.

Created by the Center for Biotechnology, this program is targeted towards graduate students and postdocs seeking to facilitate commercial activities within their academic labs or enhance their knowledge of the commercial sector in order to transition into non-academic careers.  To learn more about the program and its opportunities visit: www.fobip.org.

2021 PROGRAM EARLY APPLICATION DEADLINE – FRIDAY, OCTOBER 23 2020

[post_title] => Fundamentals of the Bioscience Industry Program - Application Open! [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => fundamentals-of-the-bioscience-industry-program-application-open [to_ping] => [pinged] => [post_modified] => 2021-04-07 20:05:05 [post_modified_gmt] => 2021-04-07 20:05:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3642 [menu_order] => 56 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2836 [post_author] => 1 [post_date] => 2017-09-29 14:45:07 [post_date_gmt] => 2017-09-29 14:45:07 [post_content] => Traverse Biosciences, lead by CFB BioEntrepreneur-in-Residence (B-EIR) Joseph Scaduto, has announced that the National Institutes of Health (NIH) has accepted the company into its competitive Commercialization Accelerator Program (CAP). Hosted in partnership with the Larta Institute, NIH CAP is a 9-month program that is well-regarded for its combination of deep domain expertise and access to industry connections, which have resulted in measurable gains and accomplishments by participating companies. It is open only to NIH SBIR/STTR Phase II awardees, with only 80 slots available each year. The program enables participants to establish market and customer relevance, build commercial relationships, and focus on revenue opportunities available to them. Last year, Traverse Biosciences announced that it had received a $1.3M Phase II Small Business Technology Transfer (STTR) award in partnership with the School of Dental Medicine at Stony Brook University. Read the full Traverse Biosciences announcement here. [post_title] => Traverse Biosciences Accepted into NIH Commercialization Accelerator Program (CAP) [post_excerpt] => CFB BEIR-led Traverse Biosciences will enter the exclusive 9-month program which enables participants to establish market and customer relevance, build commercial relationships, and focus on revenue opportunities available to them. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => traverse-biosciences-accepted-into-nih-commercialization-accelerator-program-cap [to_ping] => [pinged] => [post_modified] => 2018-01-23 14:39:02 [post_modified_gmt] => 2018-01-23 14:39:02 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2836 [menu_order] => 137 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3433 [post_author] => 3 [post_date] => 2020-01-31 19:46:34 [post_date_gmt] => 2020-01-31 19:46:34 [post_content] => BARDA is supporting US government market research to identify medical countermeasures with the potential to help address the 2019 novel coronavirus outbreak. The agency wants to hear from companies developing diagnostics, therapeutics, vaccines, or other products. They are asking for a very brief (500-word) description of the product or technology, accompanied by a quad chart slide and one other short slide deck of your choosing. Please note that while they will use any information you present as market research, submission is no guarantee of funding and your submission will be shared across U.S. Government agencies involved in nCoV countermeasure research and development. Learn More: https://medicalcountermeasures.gov/app/barda/coronavirus.aspx [post_title] => BARDA Seeking Info to Identify Countermeasure to 2019 Novel Coronovirus [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => barda-seeking-info-to-identify-countermeasure-to-2019-novel-coronovirus [to_ping] => [pinged] => [post_modified] => 2020-01-31 19:46:34 [post_modified_gmt] => 2020-01-31 19:46:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3433 [menu_order] => 76 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4488 [post_author] => 4 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 [post_content] =>

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2024-12-05 11:35:07 [post_modified_gmt] => 2024-12-05 16:35:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 256 [max_num_pages] => 86 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

More Information

Fundamentals of the Bioscience Industry Program – Application Open!

More Information

Traverse Biosciences Accepted into NIH Commercialization Accelerator Program (CAP)

More Information

BARDA Seeking Info to Identify Countermeasure to 2019 Novel Coronovirus

More Information